“Ten years ago, only a few private equity firms had dedicated healthcare components, but today, nearly everyone does” says Dmity Podpolny of McKinsey & Company, one of the largest consulting firms in the world. Private equity and medicine are now on the rise. For years, private equity firms have invested […]

As of October 24, 2018, a new regulation passed that affects the private sector of the health care industry potentially having lasting effects on clinics, laboratories and even marketing companies. Mirroring the federal Anti-Kickback Statute, the Eliminating Kickbacks in Recovery Act (“EKRA”) aims to fight the opioid epidemic. In particular, […]

The Food and Drug Administration (FDA) has had authority over cosmetics since the passing of the Food, Drug, and Cosmetic Act (FDCA) in 1938. However, this authority is based only in regulatory power, not approval power. The FDCA does not require cosmetics to acquire pre-market approval, except for cosmetics that have color […]

The United States is the most expensive market for biologic drugs, including insulin, despite initiatives devised by the Food and Drug Administration (FDA) and the Affordable Care Act. For more than a decade, the biosimilars market in the US has lagged behind the European market, whose medicines are as much […]

In the winter of 2017, the world was captivated by the rise and fall of Bitcoin. Every night during its historic rise, local news ran rags-to-riches stories of basement investors who had cashed out at the right time. Every day, bloggers, tech journalists, and finance journalists tried to diagnose the […]